Intradetrusor botulinum toxin type A in refractory overactive bladder: A potential future treatment.
作者信息
Mahajan Rajiv, Singh Navyug Raj
机构信息
Department of Pharmacology, Adesh Institute of Medical Sciences and Research, Bathinda - 151101, India.
出版信息
Int J Appl Basic Med Res. 2011 Jul;1(2):67-70. doi: 10.4103/2229-516X.91144.
Abstract
摘要
相似文献
1
Intradetrusor botulinum toxin type A in refractory overactive bladder: A potential future treatment.
Int J Appl Basic Med Res. 2011 Jul;1(2):67-70. doi: 10.4103/2229-516X.91144.
2
[Seniority of neurobladder and effectiveness of a first intradetrusor injection of botulinum toxin].
Prog Urol. 2015 Sep;25(11):642-8. doi: 10.1016/j.purol.2015.05.008. Epub 2015 Jun 17.
3
[Botulinum toxin injection for refractory non-neurogenic overactive bladder. Systematic review].
Rev Med Brux. 2015 Jan-Feb;36(1):29-37.
4
Bladder instillation of liposome encapsulated onabotulinumtoxina improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial.
J Urol. 2014 Dec;192(6):1743-9. doi: 10.1016/j.juro.2014.07.008. Epub 2014 Jul 18.
5
Botulinum toxin--a new therapeutic agent in girls with non-neurogenic overactive bladder--a case report and review of the literature.
Ginekol Pol. 2010 Nov;81(11):870-3.
6
Botulinum toxin injections for adults with overactive bladder syndrome.
Cochrane Database Syst Rev. 2011 Dec 7(12):CD005493. doi: 10.1002/14651858.CD005493.pub3.
7
Past, Present and Future of Chemodenervation with Botulinum Toxin in the Treatment of Overactive Bladder.
J Urol. 2017 Apr;197(4):982-990. doi: 10.1016/j.juro.2016.11.092. Epub 2016 Nov 18.
8
[Prospective study of the clinical and urodynamic results of intradetrusor botulinum toxin injections for the treatment of neurogenic overactive bladder].
Prog Urol. 2008 Jul;18(7):449-55. doi: 10.1016/j.purol.2008.03.014. Epub 2008 May 27.
9
Botulinum toxin and refractory non-neurogenic overactive detrusor.
Ann Phys Rehabil Med. 2009 Nov;52(9):668-83. doi: 10.1016/j.rehab.2009.07.032. Epub 2009 Aug 13.
10
[Patient follow-up after botulinum toxin intradetrusor injection. Proposal for management in neurogenic patients].
Ann Readapt Med Phys. 2008 May;51(4):315-21. doi: 10.1016/j.annrmp.2008.03.003. Epub 2008 May 7.
本文引用的文献
1
Botulinum toxin type A in patients with Parkinson's disease and refractory overactive bladder.
J Urol. 2011 Sep;186(3):960-4. doi: 10.1016/j.juro.2011.04.071. Epub 2011 Jul 24.
2
Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial.
J Urol. 2011 Jun;185(6):2229-35. doi: 10.1016/j.juro.2011.02.004. Epub 2011 Apr 16.
3
Update on the pharmacologic management of overactive bladder: the present and the future.
Urol Nurs. 2010 Jan-Feb;30(1):29-38, 53. doi: 10.7257/1053-816x.2010.30.1.29.
4
Botulinum neurotoxin type A-ABO (Dysport): clinical indications and practice guide.
Aesthet Surg J. 2009 Nov;29(6 Suppl):S72-9. doi: 10.1016/j.asj.2009.09.016.
5
Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence.
BMC Urol. 2009 Nov 20;9:18. doi: 10.1186/1471-2490-9-18.
6
Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
Eur Urol. 2009 Mar;55(3):705-11. doi: 10.1016/j.eururo.2008.08.048. Epub 2008 Sep 2.
7
Muscarinic receptor antagonists for overactive bladder.
BJU Int. 2007 Nov;100(5):987-1006. doi: 10.1111/j.1464-410X.2007.07205.x.
8
Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections.
Eur Urol. 2008 Mar;53(3):613-8. doi: 10.1016/j.eururo.2007.08.039. Epub 2007 Aug 28.
9
Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial.
J Urol. 2007 Jun;177(6):2231-6. doi: 10.1016/j.juro.2007.01.130.
10
Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.
Eur Urol. 2006 Dec;50(6):1306-14; discussion 1314-5. doi: 10.1016/j.eururo.2006.09.019. Epub 2006 Oct 2.
Zotero 插件